The Test
The quick, convenient blood test designed to rule out Esophageal Cancer for those suffering chronic reflux
The blood test that detects specific proteomic changes with a high degree of accuracy to rule out Esophageal Adenocarcinoma (EAC) in your patients with chronic reflux.
A non-invasive assessment of EAC risk
- EAC rule out (NPV) of 99.9% enables doctors to confidently manage reflux
- EAC rule in (Sensitivity) of 91.4% guides treatment decisions
How the PromarkerEso test works
Blood sample
A sample is drawn at clinic or pathology laboratory
Biomarker analysis
Laboratory uses the technique of liquid-chromatography-mass spectrometry (LC-MS) to measure serum glycoprotein biomarkers
PromarkerEso hubÂ
a software tool combines biomarkers with clinical factors in a proprietary algorithm to calculate the risk score
Clinical Management
Provides physician confidence to manage reflux without EAC concern (Low Risk), or guide interventions (Moderate/High Risk)
Results & clinical intervention
Risk profile
Recommendation
Further Managmen
Low risk
~1 in 16 chance of having EAC
- Continue with routine surveillance as recommended by healthcare provider
No
Moderate risk
~1 in 4 chance of having EAC
- Follow-up with upper GI endoscopy
Based on endoscopic examination and any biopsy conducted
High risk
>9 in 10 chance of having EAC
- Immediate (priority) referral for upper GI endoscopy
Based on endoscopic examination and any biopsy conducted
To see a detailed test report example, please click here.
Find out how PromarkerEso can make a difference
learn more about this blood test that detects specific proteomic changes with a high degree of accuracy to rule out Esophageal Adenocarcinoma in your patient suffering from chronic reflux.
